Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Treasury Shares (2023 - 2025)

Stoke Therapeutics has reported Treasury Shares over the past 3 years, most recently at $61000.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $61000.0 for Q4 2025, down 72.15% from a year ago — trailing twelve months through Dec 2025 was $61000.0 (down 72.15% YoY), and the annual figure for FY2025 was $61000.0, down 72.15%.
  • Treasury Shares for Q4 2025 was $61000.0 at Stoke Therapeutics, down from $219000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for STOK hit a ceiling of $1.5 million in Q4 2023 and a floor of $61000.0 in Q4 2025.
  • Median Treasury Shares over the past 3 years was $219000.0 (2024), compared with a mean of $597700.7.
  • Biggest five-year swings in Treasury Shares: crashed 85.53% in 2024 and later tumbled 72.15% in 2025.
  • Stoke Therapeutics' Treasury Shares stood at $1.5 million in 2023, then crashed by 85.53% to $219000.0 in 2024, then tumbled by 72.15% to $61000.0 in 2025.
  • The last three reported values for Treasury Shares were $61000.0 (Q4 2025), $219000.0 (Q4 2024), and $1.5 million (Q4 2023) per Business Quant data.